Professor of Oncology, Wayne State University
Oncology
Dr. Anthony F. Shields, MD
|
|
Give Review
Anthony F. Shields, MD works in the field of Oncology. He attended Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received 1 awards: "Super Doctor". Anthony Shields is a published doctor. He published 101 publications, including: 'Phase II study of CI-958 in colorectal cancer.'
Publications
- Percutaneous cryoablation of hepatic Tumors: long-term experience of a large U.S. series.
- A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
- Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal Cancer.
- Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
- 18F-fluoride PET used for treatment monitoring of systemic Cancer therapy: results from the National Oncologic PET Registry.
- Positron Emission Tomography for Subsequent Treatment Strategy in Oncology.
- 55p * pet/ct imaging of 64cu-labelled her2 liposomal Doxorubicin (64cu-mm-302) quantifies variability of liposomal drug deLivery to diverse tumor lesions in her2-posit...
- Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
- Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung Cancer cells to pemetrexed.
- Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry.
- PET Imaging of Proliferation with Pyrimidines.
- Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic Cancer who receive gemcitabine-containing chemotherapy: a poole...
- Simultaneous determination of 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human p...
- Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: A Single Institution Experience.
- Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
- Clinicopathological Analysis of primary epithelial appendiceal neoplasms.
- Cediranib in combination with various antiCancer regimens: results of a phase I multi-cohort study.
- Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pan...
- A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic Cancer.
- PET and PET/CT reports: observations from the National Oncologic PET Registry.
- Fatal Liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.
- The impact of positron emission tomography (PET) on expected management during Cancer treatment: findings of the National Oncologic PET Registry.
- Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.
- Relationship between Cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
- Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung Cancer.
- Imaging of cell proliferation: status and prospects.
- Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with Cancer: initial results...
- Recommendations on the use of 18F-FDG PET in oncology.
- The National Oncologic PET Registry (NOPR): design and Analysis plan.
- Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.
- A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
- The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
- Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2'-Deoxy-2'-18F-Fluoro-beta-D-arabinofuranosyl)-5-iodouracil in norm...
- Phase II trial of interferon and thalidomide in metastatic renal cell Carcinoma.
- Phase I study of bryostatin 1 and gemcitabine.
- PET of human prostate Cancer xenografts in mice with increased uptake of 64CuCl2.
- Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.
- Computerized detection of Lung tumors in PET/CT images.
- A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic Cancer.
- Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs.
- Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
- A phase II study of carboplatin and paclitaxel in adenoCarcinoma of unknown primary.
- Imaging DNA synthesis in vivo with 18F-FMAU and PET.
- PET imaging of cellular proliferation.
- Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid Tumors.
- Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic Cancer.
- Treatment of advanced coloRectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
- Efficacy and safety of reteplase for central venous catheter occlusion in patients with Cancer.
- Chemoradiotherapy in the treatment of regional pancreatic Carcinoma: a phase II study.
- PET imaging with 18F-FLT and thymidine Analogs: promise and pitfalls.
- Phase II trial of intravenous CI-1042 in patients with metastatic colorectal Cancer.
- An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor.
- Phase II study of paclitaxel and carboplatin in patients with advanced gastric Cancer.
- Clinicopathologic Analysis of pancreatic adenocarcinoma in African Americans and Caucasians.
- High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor.
- Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs.
- CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic Cancer treated with gemcitabine based chemotherapy.
- Imaging [18F]FAU [1-(2''-deoxy-2''-fluoro-beta-D-arabinofuranosyl) uracil] in dogs.
- Herpes simplex virus thymidine kinase imaging in mice with (1-(2'-deoxy-2'-[18F]fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2'-deoxy-2'-[18F]fluoro...
- Preface-imaging in Cancer.
- The role of DNA synthesis imaging in Cancer in the era of targeted therapeutics.
- Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.
- Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal Cancer.
- A simplified Analysis of [18F]3''-deoxy-3''-fluorothymidine metabolism and retention.
- Imaging the pharmacokinetics of [F-18]FAU in patients with Tumors: PET studies.
- Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with Cancer.
- Synthesis of 2''-deoxy-2''-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular ...
- A phase II trial of bryostatin 1 in the treatment of metastatic colorectal Cancer.
- Phase II study of liposomal doxorubicin in patients with advanced colorectal Cancer.
- Expression of inflammatory modulator COX-2 in pancreatic Ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
- Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an Oral prodrug of 5-fluorouracil (5FU).
- Phase II study of pyrazoloacridine in patients with advanced coloRectal carcinoma.
- Establishment of a human Pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
- Kinetic Analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical Analysis.
- Phase II study of CI-958 in colorectal Cancer.
- Radiosynthesis of 3''-deoxy-3''-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo.
- Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic Carcinoma: a phase II study.
- Impact of race, age, and socioeconomic status on participation in pancreatic Cancer clinical trials.
- Cost Analysis of pancreatic carcinoma treatment.
- Evaluation of pyrazoloacridine in patients with advanced pancreatic Carcinoma.
- Kinetic Analysis of 2-[11C]thymidine PET imaging studies: validation studies.
- Radiosyntheses of labeled beta-pseudothymidine ([C-11]- and [H-3]methyl) and its biodistribution and metabolism in normal and tumored mice.
- Gemcitabine and UFT plus Oral calcium folinate: phase I study.
- Carbon-11-thymidine and FDG to measure therapy response.
- A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric Cancer.
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal Malignancies.
- Radiographic parameters in predicting outcome of patients with hepatocellular Carcinoma treated with yttrium-90 microsphere radioembolization.
- Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic Carcinoma.
- Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic Cancer.
- A novel computerized approach to enhancing Lung tumor detection in whole-body PET images.
- 5-Fluoro-1-(2'-deoxy-2'-fluoro-beta-D-ribofuranosyl) uracil trapping in Morris hepatoma cells expressing the herpes simplex virus thymidine kinase gene.
- Development of labeled thymidine Analogs for imaging tumor proliferation.
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction Cancers.
- A graphical Analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites.
- Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.
- Characterizing Tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.
- Utilization of labeled thymidine in DNA synthesis: studies for PET.
- The role of imaging in the development of oncologic agents.
- Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds.
- A phase II study of carboplatin and paclitaxel in esophageal Cancer.
Schools
Harvard Medical School
University Wash Hospital
University of Washington
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Washington -
Harvard Medical School
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1629016746 | |
| NPPES Provider LastName | SHIELDS | |
| NPPES Provider FirstName | ANTHONY | |
| NPPES Provider ZIPCode | 482012013 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 277.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 9.75 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629016746 |
| Last Name Of The Provider | SHIELDS |
| First Name Of The Provider | ANTHONY |
| View All |
Similar Doctors
|
Dr. Steven J. Gamalski, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judith C. Andersen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elisabeth I. Heath, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ulka N. Vaishampayan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay Yang, MD |
|
|
Dr. Charles A. Schiffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Ensley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmed O. Kaseb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy M. Weise, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravneet Thind, MD |
|
|
Dr. Hetal R. Vachhani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shirish M. Gadgeel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Randa Loutfi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Belisario A. Arango, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ananda S. Prasad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sana A. Al Sukhun |